Related references
Note: Only part of the references are listed.Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland
Zoe Grange et al.
LANCET (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof et al.
LANCET (2021)
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels et al.
NATURE MEDICINE (2021)
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans
Yinong Young-Xu et al.
JAMA NETWORK OPEN (2021)
Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients
Syed Ali Husain et al.
KIDNEY INTERNATIONAL REPORTS (2021)
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh et al.
LANCET (2021)
Vaccine Effectiveness Studies in the Field
Stephen J. W. Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce
Jocelyn Keehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
S. J. Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients
Saima Aslam et al.
TRANSPLANT INFECTIOUS DISEASE (2021)
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
Eli S. Rosenberg et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
Srinivas Nanduri et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
Mark W. Tenforde et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
Catherine M. Brown et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021
Shaun J. Grannis et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
Wesley H. Self et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)